You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
|
---|---|
Published in |
Orphanet Journal of Rare Diseases, November 2012
|
DOI | 10.1186/1750-1172-7-91 |
Pubmed ID | |
Authors |
Dominique P Germain, Roberto Giugliani, Derralynn A Hughes, Atul Mehta, Kathy Nicholls, Laura Barisoni, Charles J Jennette, Alexander Bragat, Jeff Castelli, Sheela Sitaraman, David J Lockhart, Pol F Boudes |
Abstract |
Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. We report on the safety and pharmacodynamics of migalastat hydrochloride, an investigational pharmacological chaperone given orally at 150 mg every-other-day. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 1% |
Italy | 1 | 1% |
Unknown | 88 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 16 | 18% |
Student > Master | 16 | 18% |
Student > Bachelor | 11 | 12% |
Student > Ph. D. Student | 9 | 10% |
Professor > Associate Professor | 5 | 6% |
Other | 12 | 13% |
Unknown | 21 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 28% |
Biochemistry, Genetics and Molecular Biology | 15 | 17% |
Agricultural and Biological Sciences | 12 | 13% |
Chemistry | 5 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Other | 8 | 9% |
Unknown | 21 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2018.
All research outputs
#3,026,270
of 25,374,917 outputs
Outputs from Orphanet Journal of Rare Diseases
#401
of 3,105 outputs
Outputs of similar age
#27,984
of 285,320 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#5
of 39 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,320 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.